Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$126.85 USD

126.85
3,310,764

+1.06 (0.84%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $126.90 +0.05 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (202 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NVO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Novo Nordisk AS falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 4,730 3,724 3,051 1,954 2,348
Receivables 10,928 8,143 7,446 4,931 4,370
Notes Receivable 0 0 0 0 0
Inventories 4,619 3,453 3,122 2,840 2,644
Other Current Assets 0 0 0 357 0
Total Current Assets 20,277 15,320 13,618 10,082 9,362
Net Property & Equipment 13,208 9,441 8,808 7,701 7,578
Investments & Advances 241 190 229 252 271
Other Non-Current Assets 208 29 42 103 126
Deferred Charges 2,959 1,901 1,380 899 618
Intangibles 8,771 7,281 6,869 3,165 875
Deposits & Other Assets 0 0 0 0 0
Total Assets 45,663 34,162 30,946 22,202 18,829
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 3,718 2,207 1,411 876 953
Current Portion Long-Term Debt 941 208 2,177 1,143 221
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 1,033 1,004 582 599 631
Other Current Liabilities 18,942 13,706 11,663 8,148 7,036
Total Current Liabilities 24,634 17,125 15,833 10,766 8,842
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1,476 1,000 839 383 12
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,981 3,443 2,062 444 451
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,101 772 957 908 891
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 30,191 22,340 19,691 12,501 10,196
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 65 65 74 72 72
Capital Surplus 0 0 0 0 0
Retained Earnings 15,223 11,411 11,456 9,770 8,667
Other Equity 185 347 -273 -140 -104
Treasury Stock 1 1 1 1 2
Total Shareholder's Equity 15,473 11,822 11,256 9,701 8,633
Total Liabilities & Shareholder's Equity 45,663 34,162 30,946 22,202 18,829
Total Common Equity 15,473 11,822 11,256 9,701 8,633
Shares Outstanding 4,487.50 4,525.90 4,709.60 4,709.60 4,736.00
Book Value Per Share 3.45 2.61 2.39 2.06 1.82

Fiscal Year End for Novo Nordisk AS falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 4,730 7,402 5,699 4,382
Receivables NA 10,928 9,047 10,303 8,346
Notes Receivable NA 0 0 0 0
Inventories NA 4,619 4,312 4,094 3,691
Other Current Assets NA 0 0 0 0
Total Current Assets NA 20,277 20,761 20,096 16,419
Net Property & Equipment NA 13,208 11,893 10,961 10,089
Investments & Advances NA 241 215 216 175
Other Non-Current Assets NA 208 63 49 42
Deferred Charges NA 2,959 2,747 2,281 2,029
Intangibles NA 8,771 8,136 7,414 7,275
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 45,663 43,815 41,018 36,029
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 3,718 2,935 2,599 1,448
Current Portion Long-Term Debt NA 941 966 919 180
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 1,033 1,795 1,405 874
Other Current Liabilities NA 18,942 19,496 17,959 16,514
Total Current Liabilities NA 24,634 25,193 22,882 19,016
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 1,476 1,151 1,114 1,135
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 2,981 2,909 2,837 3,497
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 985 967 872
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 30,191 30,238 27,800 24,519
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 65 66 66 66
Capital Surplus NA 0 0 0 0
Retained Earnings NA 15,223 13,393 12,874 11,106
Other Equity NA 185 118 279 339
Treasury Stock NA 1 1 0 1
Total Shareholder's Equity NA 15,473 13,577 13,218 11,510
Total Liabilities & Shareholder's Equity NA 45,663 43,815 41,018 36,029
Total Common Equity 0 15,473 13,577 13,218 11,510
Shares Outstanding 4,487.50 4,487.50 4,487.50 4,487.50 4,525.90
Book Value Per Share 0.00 3.45 3.03 2.95 2.54